Search Results
PFS Data Support Approval of Fam-Trastuzumab Deruxtecan-nxki for HER2+ Breast Cancer
Trastuzumab Deruxtecan in HER2+ Breast Cancer
New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. Gradishar
Targeting HER2 in Advanced Solid Tumors: A Comprehensive Understanding of the Rationale and Poten...
Trastuzumab Deruxtecan for Breast Cancer | NEJM
Margetuximab for the treatment of HER2-positive breast cancer
Dr. Peters Discusses Ongoing Research With Trastuzumab Deruxtecan in NSCLC
Research Update on Metastatic Breast Cancer
Salvatore Siena, MD, explains the mechanism of action of trastuzumab deruxtecan and its promise
FDA APPROVED THERAPY FOR NEW BREAST CANCER
Dr. Janjigian on Pembrolizumab Triplet in HER2+ Esophagogastric Cancer
Breast cancer: Two new drugs for HER2
